Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Festa, A.
Right arrow Articles by Haffner, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Festa, A.
Right arrow Articles by Haffner, S. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 51:1131-1137, 2002
© 2002 by the American Diabetes Association, Inc.

Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes

The Insulin Resistance Atherosclerosis Study

Andreas Festa1, Ralph D’Agostino, Jr2, Russell P. Tracy3, and Steven M. Haffner1

1 Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas
2 Department of Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, North Carolina
3 Laboratory for Clinical Biochemistry Research, Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont

Elevated serum levels of acute-phase proteins, indicating chronic subclinical inflammation, have been associated with cardiovascular disease as well as the insulin resistance syndrome. Chronic inflammation may also be a risk factor for developing type 2 diabetes. We studied the concentrations of C-reactive protein (CRP), fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) in 1,047 nondiabetic subjects in relation to incident diabetes within 5 years in the Insulin Resistance Atherosclerosis Study. Subjects with diabetes at follow-up (n = 144) had higher baseline levels of fibrinogen (mean ± SD; 287.8 ± 58.8 vs. 275.1 ± 56.0 mg/dl; P = 0.013) as well as of CRP (median [interquartile range]; 2.40 [1.29, 5.87] vs. 1.67 mg/l [0.75, 3.41]; P = 0.0001) and PAI-1 (24 [15, 37.5] vs. 16 ng/ml [9, 27]; P = 0.0001) than nonconverters. The odds ratio (OR) of converting to diabetes was significantly increased with increasing baseline concentrations of the inflammatory markers. In contrast to PAI-1, the association of CRP and fibrinogen with incident diabetes was significantly attenuated after adjustment for body fat (BMI or waist circumference) or insulin sensitivity (SI), as assessed by a frequently sampled intravenous glucose tolerance test. In a logistic regression model that included age, sex, ethnicity, clinical center, smoking, BMI, SI, physical activity, and family history of diabetes, PAI-1 still remained significantly related to incident type 2 diabetes (OR [95% CI] for 1 SD increase: 1.61 [1.20–2.16]; P = 0.002). Chronic inflammation emerges as a new risk factor for the development of type 2 diabetes; PAI-1 predicts type 2 diabetes independent of insulin resistance and other known risk factors for diabetes.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
J. H. Ix, C. L. Wassel, A. M. Kanaya, E. Vittinghoff, K. C. Johnson, A. Koster, J. A. Cauley, T. B. Harris, S. R. Cummings, M. G. Shlipak, et al.
Fetuin-A and Incident Diabetes Mellitus in Older Persons
JAMA, July 9, 2008; 300(2): 182 - 188.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague
Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study
Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2250 - 2257.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. M. Pou, J. M. Massaro, U. Hoffmann, R. S. Vasan, P. Maurovich-Horvat, M. G. Larson, J. F. Keaney Jr, J. B. Meigs, I. Lipinska, S. Kathiresan, et al.
Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress: The Framingham Heart Study
Circulation, September 11, 2007; 116(11): 1234 - 1241.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. Ingelsson, M. J. Pencina, G. H. Tofler, E. J. Benjamin, K. J. Lanier, P. F. Jacques, C. S. Fox, J. B. Meigs, D. Levy, M. G. Larson, et al.
Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study
Circulation, August 28, 2007; 116(9): 984 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. Liu, L. Tinker, Y. Song, N. Rifai, D. E. Bonds, N. R. Cook, G. Heiss, B. V. Howard, G. S. Hotamisligil, F. B. Hu, et al.
A Prospective Study of Inflammatory Cytokines and Diabetes Mellitus in a Multiethnic Cohort of Postmenopausal Women
Arch Intern Med, August 13, 2007; 167(15): 1676 - 1685.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
G. Yuan, X. Chen, Q. Ma, J. Qiao, R. Li, X. Li, S. Li, J. Tang, L. Zhou, H. Song, et al.
C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes
J. Endocrinol., August 1, 2007; 194(2): 275 - 281.
[Abstract] [Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
B. K. Pedersen
State of the Art Reviews: Health Benefits Related to Exercise in Patients With Chronic Low-Grade Systemic Inflammation
American Journal of Lifestyle Medicine, August 1, 2007; 1(4): 289 - 298.
[Abstract] [PDF]

Home page
 J. Nutr.Home page
J. Shen, D. K. Arnett, J. M. Peacock, L. D. Parnell, A. Kraja, J. E. Hixson, M. Y. Tsai, C.-Q. Lai, E. K. Kabagambe, R. J. Straka, et al.
Interleukin1{beta} Genetic Polymorphisms Interact with Polyunsaturated Fatty Acids to Modulate Risk of the Metabolic Syndrome
J. Nutr., August 1, 2007; 137(8): 1846 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J. K Devin, J. E Johnson, M. Eren, L. A Gleaves, W. S Bradham, J. R Bloodworth Jr, and D. E Vaughan
Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice
J. Mol. Endocrinol., July 1, 2007; 39(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. J.G. Hanley, L. E. Wagenknecht, A. Festa, R. B. D'Agostino Jr., and S. M. Haffner
Alanine Aminotransferase and Directly Measured Insulin Sensitivity in a Multiethnic Cohort: The Insulin Resistance Atherosclerosis Study
Diabetes Care, July 1, 2007; 30(7): 1819 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
B. R. Celli and P. J. Barnes
Exacerbations of chronic obstructive pulmonary disease
Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]

Home page
 DiabetesHome page
T. Nakamachi, T. Nomiyama, F. Gizard, E. B. Heywood, K. L. Jones, Y. Zhao, L. Fuentes, K. Takebayashi, Y. Aso, B. Staels, et al.
PPAR{alpha} Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes
Diabetes, June 1, 2007; 56(6): 1662 - 1670.
[Abstract] [Full Text] [PDF]

Home page
 Epidemiol RevHome page
G. Vazquez, S. Duval, D. R. Jacobs Jr., and K. Silventoinen
Comparison of Body Mass Index, Waist Circumference, and Waist/Hip Ratio in Predicting Incident Diabetes: A Meta-Analysis
Epidemiol. Rev., May 10, 2007; (2007) mxm008v1.
[Abstract] [Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. G. Flynn, B. K. McFarlin, and M. M. Markofski
State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training
American Journal of Lifestyle Medicine, May 1, 2007; 1(3): 220 - 235.
[Abstract] [PDF]

Home page
 Am J EpidemiolHome page
T. B. Harris, L. J. Launer, G. Eiriksdottir, O. Kjartansson, P. V. Jonsson, G. Sigurdsson, G. Thorgeirsson, T. Aspelund, M. E. Garcia, M. F. Cotch, et al.
Age, Gene/Environment Susceptibility-Reykjavik Study: Multidisciplinary Applied Phenomics
Am. J. Epidemiol., May 1, 2007; 165(9): 1076 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. I. Kakafika, D. P. Mikhailidis, A. Karagiannis, and V. G. Athyros
The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome
J. Clin. Pharmacol., May 1, 2007; 47(5): 642 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Thorand, J. Baumert, H. Kolb, C. Meisinger, L. Chambless, W. Koenig, and C. Herder
Sex Differences in the Prediction of Type 2 Diabetes by Inflammatory Markers: Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002
Diabetes Care, April 1, 2007; 30(4): 854 - 860.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Dehghan, I. Kardys, M. P.M. de Maat, A. G. Uitterlinden, E. J.G. Sijbrands, A. H. Bootsma, T. Stijnen, A. Hofman, M. T. Schram, and J. C.M. Witteman
Genetic Variation, C-Reactive Protein Levels, and Incidence of Diabetes
Diabetes, March 1, 2007; 56(3): 872 - 878.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. J. Creely, P. G. McTernan, C. M. Kusminski, ff. M. Fisher, N. F. Da Silva, M. Khanolkar, M. Evans, A. L. Harte, and S. Kumar
Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E740 - E747.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. P. Donahue, K. Rejman, L. B. Rafalson, J. Dmochowski, S. Stranges, and M. Trevisan
Sex Differences in Endothelial Function Markers Before Conversion to Pre-Diabetes: Does the Clock Start Ticking Earlier Among Women?: The Western New York Study
Diabetes Care, February 1, 2007; 30(2): 354 - 359.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. G. de Vinuesa, M. Goicoechea, J. Kanter, M. Puerta, V. Cachofeiro, V. Lahera, F. Gomez-Campdera, and J. Luno
Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S206 - S212.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. M. De Taeye, T. Novitskaya, L. Gleaves, J. W. Covington, and D. E. Vaughan
Bone Marrow Plasminogen Activator Inhibitor-1 Influences the Development of Obesity
J. Biol. Chem., October 27, 2006; 281(43): 32796 - 32805.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Libby and P. M. Ridker
Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. L.G. Correia and W. G. Haynes
A Role for Plasminogen Activator Inhibitor-1 in Obesity: From Pie to PAI?
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2183 - 2185.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. L. Crandall, E. M. Quinet, S. El Ayachi, A. L. Hreha, C. E. Leik, D. A. Savio, I. Juhan-Vague, and M.-C. Alessi
Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2209 - 2215.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M.-C. Alessi and I. Juhan-Vague
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2200 - 2207.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
N. de Rekeneire, R. Peila, J. Ding, L. H. Colbert, M. Visser, R. I. Shorr, S. B. Kritchevsky, L. H. Kuller, E. S. Strotmeyer, A. V. Schwartz, et al.
Diabetes, Hyperglycemia, and Inflammation in Older Individuals: The Health, Aging and Body Composition study
Diabetes Care, August 1, 2006; 29(8): 1902 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Herder, M. Peltonen, W. Koenig, I. Kraft, S. Muller-Scholze, S. Martin, T. Lakka, P. Ilanne-Parikka, J. G. Eriksson, H. Hamalainen, et al.
Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes: Results From the Finnish Diabetes Prevention Study.
Diabetes, August 1, 2006; 55(8): 2340 - 2346.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. E. Kahn, B. Zinman, S. M. Haffner, M. C. O'Neill, B. G. Kravitz, D. Yu, M. I. Freed, W. H. Herman, R. R. Holman, N. P. Jones, et al.
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
Diabetes, August 1, 2006; 55(8): 2357 - 2364.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
N. R. Cook, J. E. Buring, and P. M Ridker
The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women
Ann Intern Med, July 4, 2006; 145(1): 21 - 29.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
G. Efstratiadis, G. Tsiaousis, V. G. Athyros, D. Karagianni, A. Pavlitou-Tsiontsi, A. Giannakou-Darda, and C. Manes
Total Serum Insulin-like Growth Factor-1 and C-Reactive Protein in Metabolic Syndrome With or Without Diabetes
Angiology, May 1, 2006; 57(3): 303 - 311.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
J. Nigro, N. Osman, A. M. Dart, and P. J. Little
Insulin Resistance and Atherosclerosis
Endocr. Rev., May 1, 2006; 27(3): 242 - 259.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Sell, D. Dietze-Schroeder, U. Kaiser, and J. Eckel
Monocyte Chemotactic Protein-1 Is a Potential Player in the Negative Cross-Talk between Adipose Tissue and Skeletal Muscle
Endocrinology, May 1, 2006; 147(5): 2458 - 2467.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Tsimikas, J. T. Willerson, and P. M. Ridker
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Festa, K. Williams, R. P. Tracy, L. E. Wagenknecht, and S. M. Haffner
Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes
Circulation, April 11, 2006; 113(14): 1753 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Lobner, A. Knopff, A. Baumgarten, U. Mollenhauer, S. Marienfeld, M. Garrido-Franco, E. Bonifacio, and A.-G. Ziegler
Predictors of Postpartum Diabetes in Women With Gestational Diabetes Mellitus
Diabetes, March 1, 2006; 55(3): 792 - 797.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. M. Kanaya, C. Wassel Fyr, E. Vittinghoff, T. B. Harris, S. W. Park, B. H. Goodpaster, F. Tylavsky, and S. R. Cummings
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
Arch Intern Med, February 13, 2006; 166(3): 350 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C. Herder, S. Muller-Scholze, P. Rating, W. Koenig, B. Thorand, B. Haastert, R. Holle, T. Illig, W. Rathmann, J. Seissler, et al.
Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4)
Eur. J. Endocrinol., February 1, 2006; 154(2): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. B. Meigs, C. J. O'Donnell, G. H. Tofler, E. J. Benjamin, C. S. Fox, I. Lipinska, D. M. Nathan, L. M. Sullivan, R. B. D'Agostino, and P. W.F. Wilson
Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes: The Framingham Offspring Study
Diabetes, February 1, 2006; 55(2): 530 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. A. Bhatt, J. J. Dube, N. Dedousis, J. A. Reider, and R. M. O'Doherty
Diet-induced obesity and acute hyperlipidemia reduce I{kappa}B{alpha} levels in rat skeletal muscle in a fiber-type dependent manner
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R233 - R240.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. J.G. Hanley, A. J. Karter, K. Williams, A. Festa, R. B. D'Agostino Jr, L. E. Wagenknecht, and S. M. Haffner
Prediction of Type 2 Diabetes Mellitus With Alternative Definitions of the Metabolic Syndrome: The Insulin Resistance Atherosclerosis Study
Circulation, December 13, 2005; 112(24): 3713 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Herder, B. Haastert, S. Muller-Scholze, W. Koenig, B. Thorand, R. Holle, H.-E. Wichmann, W. A. Scherbaum, S. Martin, and H. Kolb
Association of Systemic Chemokine Concentrations With Impaired Glucose Tolerance and Type 2 Diabetes: Results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4)
Diabetes, December 1, 2005; 54(suppl_2): S11 - S17.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. J.G. Hanley, K. Williams, A. Festa, L. E. Wagenknecht, R. B. D'Agostino Jr, and S. M. Haffner
Liver Markers and Development of the Metabolic Syndrome: The Insulin Resistance Atherosclerosis Study
Diabetes, November 1, 2005; 54(11): 3140 - 3147.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. R. Johnson, J. C. O'Connor, R. Dantzer, and G. G. Freund
Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness
PNAS, October 18, 2005; 102(42): 15184 - 15189.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Y. Doi, Y. Kiyohara, M. Kubo, T. Ninomiya, Y. Wakugawa, K. Yonemoto, M. Iwase, and M. Iida
Elevated C-Reactive Protein Is a Predictor of the Development of Diabetes in a General Japanese Population: The Hisayama Study
Diabetes Care, October 1, 2005; 28(10): 2497 - 2500.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Thorand, H. Kolb, J. Baumert, W. Koenig, L. Chambless, C. Meisinger, T. Illig, S. Martin, and C. Herder
Elevated Levels of Interleukin-18 Predict the Development of Type 2 Diabetes: Results From the MONICA/KORA Augsburg Study, 1984-2002
Diabetes, October 1, 2005; 54(10): 2932 - 2938.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. Feinbloom and K. A. Bauer
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2043 - 2053.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
J. Y. King, R. Ferrara, R. Tabibiazar, J. M. Spin, M. M. Chen, A. Kuchinsky, A. Vailaya, R. Kincaid, A. Tsalenko, D. X.-F. Deng, et al.
Pathway analysis of coronary atherosclerosis
Physiol Genomics, September 21, 2005; 23(1): 103 - 118.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Kathiresan, S. B. Gabriel, Q. Yang, A. L. Lochner, M. G. Larson, D. Levy, G. H. Tofler, J. N. Hirschhorn, and C. J. O'Donnell
Comprehensive Survey of Common Genetic Variation at the Plasminogen Activator Inhibitor-1 Locus and Relations to Circulating Plasminogen Activator Inhibitor-1 Levels
Circulation, September 20, 2005; 112(12): 1728 - 1735.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Bozzini, D. Girelli, O. Olivieri, N. Martinelli, A. Bassi, G. De Matteis, I. Tenuti, V. Lotto, S. Friso, F. Pizzolo, et al.
Prevalence of Body Iron Excess in the Metabolic Syndrome
Diabetes Care, August 1, 2005; 28(8): 2061 - 2063.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. K. Hennan, H. Elokdah, M. Leal, A. Ji, G. S. Friedrichs, G. A. Morgan, R. E. Swillo, T. M. Antrilli, A. Hreha, and D. L. Crandall
Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 710 - 716.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. Dietze-Schroeder, H. Sell, M. Uhlig, M. Koenen, and J. Eckel
Autocrine Action of Adiponectin on Human Fat Cells Prevents the Release of Insulin Resistance-Inducing Factors
Diabetes, July 1, 2005; 54(7): 2003 - 2011.
[Abstract]